Sales of sofosbuvir, new Gilead hepatitis C drug, soar to $10.3 billion

The new hepatitis C drug sofosbuvir (Sovaldi—Gilead Sciences) saw $10.3 billion in sales last year, almost becoming the world's best-selling drug in its first year on the market. The autoimmune disease drug adalimumab (Humira—AbbVie), considered the world's top-selling pharmaceutical, recorded $12.5 billion in sales recorded in 2014.

The new hepatitis C drug sofosbuvir (Sovaldi—Gilead Sciences) saw $10.3 billion in sales last year, almost becoming the world's best-selling drug in its first year on the market. The autoimmune disease drug adalimumab (Humira—AbbVie), considered the world's top-selling pharmaceutical, recorded $12.5 billion in sales recorded in 2014. Sofosbuvir sales might have been higher without the introduction of the newer hepatitis C drug combination, ledipasvir-sofosbuvir (Harvoni—Gilead Sciences), which recorded $2.1 billion in sales since being approved in October. Together, sales of sofosbuvir and ledipasvir-sofosbuvir reached $12.4 billion in sales. Nearly all sales for these new drugs were in the United States.